| Effect of intrapulmonary tetrahydrocannabinol administration in humans L Zuurman, C Roy, RC Schoemaker, A Hazekamp, J Den Hartigh, ... Journal of psychopharmacology 22 (7), 707-716, 2008 | 163 | 2008 |
| Modelling of the concentration—Effect relationship of THC on central nervous system parameters and heart rate—Insight into its mechanisms of action and a tool for clinical … A Strougo, L Zuurman, C Roy, JL Pinquier, JMA Van Gerven, AF Cohen, ... Journal of Psychopharmacology 22 (7), 717-726, 2008 | 85 | 2008 |
| Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation X Bertagna, H Escourolle, JL Pinquier, J Coste, MC Raux-Demay, ... The Journal of Clinical Endocrinology & Metabolism 78 (2), 375-380, 1994 | 62 | 1994 |
| Synthesis and in vivo imaging properties of [11C] befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A F Dolle, H Valette, Y Bramoulle, I Guenther, C Fuseau, C Coulon, ... Bioorganic & medicinal chemistry letters 13 (10), 1771-1775, 2003 | 55 | 2003 |
| Effect of the binding of isradipine and darodipine to different plasma proteins on their transfer through the rat blood-brain barrier. Drug binding to lipoproteins does not … S Urien, JL Pinquier, B Paquette, P Chaumet-Riffaud, JR Kiechel, ... Journal of Pharmacology and Experimental Therapeutics 242 (1), 349-353, 1987 | 53 | 1987 |
| Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625 L Zuurman, C Roy, RC Schoemaker, A Amatsaleh, L Guimaeres, ... Journal of Psychopharmacology 24 (3), 363-371, 2010 | 49 | 2010 |
| The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers E Legangneux, J McEwen, KA Wesnes, L Bergougnan, N Miget, M Canal, ... Journal of Psychopharmacology 14 (2), 164-171, 2000 | 48 | 2000 |
| Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C] befloxatone M Bottlaender, F Dollé, I Guenther, D Roumenov, C Fuseau, Y Bramoulle, ... Journal of Pharmacology and Experimental Therapeutics 305 (2), 467-473, 2003 | 43 | 2003 |
| Relationship between low‐density lipoprotein cholesterol, free proprotein convertase subtilisin/kexin type 9, and alirocumab levels after different lipid‐lowering strategies J Rey, F Poitiers, T Paehler, A Brunet, AT DiCioccio, CP Cannon, ... Journal of the American Heart Association 5 (6), e003323, 2016 | 42 | 2016 |
| Role of alpha‐1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin S Urien, E Albengres, JL Pinquier, JP Tillement Clinical Pharmacology & Therapeutics 39 (6), 683-689, 1986 | 36 | 1986 |
| Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9‐tetrahydrocannabinol‐induced central nervous system and heart rate effects in humans LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ... British Journal of Clinical Pharmacology 76 (1), 65-77, 2013 | 31 | 2013 |
| Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9‐tetrahydrocannabinol‐induced central nervous system and heart rate effects in humans LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ... British Journal of Clinical Pharmacology 76 (1), 65-77, 2013 | 31 | 2013 |
| Pharmacological criteria for risk-benefit evaluation of NSAIDs E Albengres, JL Pinquier, P Riant, F Bree, S Urien, J Barre, JP Tillement Scandinavian Journal of Rheumatology 17 (sup73), 3-15, 1988 | 24 | 1988 |
| Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract J Stechl, I Nowotny, C Pfeiffer, JL Pinquier, J Msihid | 21 | 2013 |
| Inhibition of histamine‐induced skin wheal and flare after 5 days of mizolastine JL Pinquier, H Caplain, MJ Cabanis, C Dubruc, A Stalla‐Bourdillon, ... The Journal of Clinical Pharmacology 36 (1), 72-78, 1996 | 19 | 1996 |
| Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system J Stechl, I Nowotny, C Pfeiffer, JL Pinquier, J Msihid | 18 | 2013 |
| Pharmaceutical combination for use in glycemic control in diabetes type 2 patients P Ruus, L Silvestre, P Miossec, JL Pinquier, A Hincelin-mery US Patent App. 13/469,633, 2013 | 18 | 2013 |
| Randomized, partial blind study of the pharmacodynamics, pharmacokinetics and safety of multiple subcutaneous doses of alirocumab, a fully human monoclonal antibody to … J Rey, F Poitiers, T Paehler, A Brunet, JL Pinquier, C Hanotin, B Sasiela Journal of the American College of Cardiology 63 (12S), A1375-A1375, 2014 | 15 | 2014 |
| Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects J Tillner, A Lehmann, T Paehler, Z Lukacs, S Ruf, T Sadowski, JL Pinquier, ... Clinical Pharmacology in Drug Development 5 (1), 57-68, 2016 | 11 | 2016 |
| Bioequivalence of a new once-a-day controlled-release alfuzosin formulation with the immediate-release alfuzosin C Rauch, P Ahtoy, JL Pinquier, C Dubruc, JP Thénot Eur. J. Urol 37, 119, 2000 | 11 | 2000 |
